HK1198288A1 - Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate - Google Patents

Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate Download PDF

Info

Publication number
HK1198288A1
HK1198288A1 HK14111805.6A HK14111805A HK1198288A1 HK 1198288 A1 HK1198288 A1 HK 1198288A1 HK 14111805 A HK14111805 A HK 14111805A HK 1198288 A1 HK1198288 A1 HK 1198288A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
weight
controlled release
release layer
group
Prior art date
Application number
HK14111805.6A
Other languages
English (en)
Chinese (zh)
Inventor
．法納拉
D．法纳拉
．艾克曼
F．艾克曼
．貝爾韋爾
M．贝尔韦尔
Original Assignee
Ucb医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb医药有限公司 filed Critical Ucb医药有限公司
Publication of HK1198288A1 publication Critical patent/HK1198288A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK14111805.6A 2008-11-18 2014-11-21 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate HK1198288A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP08105817.4 2008-11-18
EP09100311.1 2009-06-02
EP09100311 2009-06-02

Publications (1)

Publication Number Publication Date
HK1198288A1 true HK1198288A1 (en) 2015-03-27

Family

ID=41395028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111805.6A HK1198288A1 (en) 2008-11-18 2014-11-21 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Country Status (18)

Country Link
US (1) US8460712B2 (enExample)
EP (1) EP2358361B1 (enExample)
JP (2) JP5954889B2 (enExample)
KR (2) KR101788804B1 (enExample)
CN (2) CN104083341A (enExample)
AU (1) AU2009317279B2 (enExample)
BR (1) BRPI0921301A2 (enExample)
CA (1) CA2741038C (enExample)
DK (1) DK2358361T3 (enExample)
EA (1) EA019583B1 (enExample)
ES (1) ES2602606T3 (enExample)
HK (1) HK1198288A1 (enExample)
HU (1) HUE030963T2 (enExample)
IL (1) IL212271A (enExample)
MX (1) MX356281B (enExample)
PL (1) PL2358361T3 (enExample)
PT (1) PT2358361T (enExample)
WO (1) WO2010057869A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2358360T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
CA3216586A1 (en) * 2021-05-11 2022-11-17 Caroline Roussel-Maupetit Prolonged-release pharmaceutical composition for oral administration of sultiame
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
WO2025128057A1 (en) * 2023-12-13 2025-06-19 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A sachet formulation comprising brivaracetam

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
NZ556630A (en) 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
US8431156B2 (en) 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
EP1863453A2 (en) * 2005-03-29 2007-12-12 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
CN101506157B (zh) * 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
KR101468053B1 (ko) * 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
WO2008062446A2 (en) 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
PL2187875T3 (pl) * 2007-09-21 2013-01-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
PT2273975E (pt) 2008-03-03 2014-07-17 Ucb Pharma Sa Processos de preparação e utilizações terapêuticas de soluções farmacêuticas

Also Published As

Publication number Publication date
DK2358361T3 (en) 2016-12-12
PT2358361T (pt) 2016-11-18
PL2358361T3 (pl) 2017-02-28
KR20170007528A (ko) 2017-01-18
AU2009317279B2 (en) 2013-10-24
AU2009317279A1 (en) 2010-05-27
JP2015143256A (ja) 2015-08-06
CN102215828A (zh) 2011-10-12
CA2741038A1 (en) 2010-05-27
KR20110089184A (ko) 2011-08-04
EA201100753A1 (ru) 2012-01-30
CA2741038C (en) 2015-01-13
WO2010057869A1 (en) 2010-05-27
EP2358361B1 (en) 2016-09-14
JP5954889B2 (ja) 2016-07-20
BRPI0921301A2 (pt) 2015-12-29
CN104083341A (zh) 2014-10-08
MX2011004572A (es) 2011-06-17
US8460712B2 (en) 2013-06-11
US20110274762A1 (en) 2011-11-10
EA019583B1 (ru) 2014-04-30
JP2012509356A (ja) 2012-04-19
IL212271A0 (en) 2011-06-30
EP2358361A1 (en) 2011-08-24
MX356281B (es) 2018-05-22
ES2602606T3 (es) 2017-02-21
KR101788804B1 (ko) 2017-10-20
IL212271A (en) 2016-10-31
HUE030963T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
CN102215829B (zh) 含有2-氧代-1-吡咯烷衍生物的延长释放制剂
AU2010215646B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
KR101257918B1 (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 서방형 약학 조성물 및 이의 제조방법
HK1198288A1 (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159503B (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
CA2635949A1 (en) Controlled release formulation of divalproic acid and its derivatives